Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study

To evaluate the ability of neoadjuvant axitinib to reduce the size of T2 renal cell carcinoma (RCC) for shifting from a radical nephrectomy (RN) to a partial nephrectomy (PN) indication, offering preservation of renal function.

[1]  A. Hahn,et al.  Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma , 2018, Current Treatment Options in Oncology.

[2]  Jeffrey A. Cadeddu,et al.  Adult Urology Oncology : Adrenal / Renal / Upper Tract / Bladder lized Renal Cancer : AUA Guideline , 2017 .

[3]  R. Autorino,et al.  Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. , 2017, European urology.

[4]  G. Oades,et al.  Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer. , 2016, JAMA oncology.

[5]  J. Kaouk,et al.  A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. , 2015, The Journal of urology.

[6]  U. Capitanio,et al.  Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function. , 2015, European urology.

[7]  I. Derweesh,et al.  Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. , 2015, Urologic oncology.

[8]  Z. Ji,et al.  Sorafenib Neoadjuvant Therapy in the Treatment of High Risk Renal Cell Carcinoma , 2015, PloS one.

[9]  K. Ahrar,et al.  Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. , 2014, European urology.

[10]  R. Figlin,et al.  Kidney cancer: Progress and controversies in neoadjuvant therapy , 2014, Nature Reviews Urology.

[11]  E. Messing,et al.  Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. , 2014, European urology.

[12]  R. Motzer,et al.  Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[13]  B. Escudier,et al.  Neoadjuvant treatment in advanced renal cell carcinoma: current situation and future perspectives , 2012, Expert review of anticancer therapy.

[14]  J. Kaouk,et al.  The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. , 2012, The Journal of urology.

[15]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[16]  C. Lohse,et al.  Outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy. , 2010, The Journal of urology.

[17]  E. Klein,et al.  Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. , 2009, The Journal of urology.

[18]  J. Haanen,et al.  Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response , 2008, Clinical Cancer Research.

[19]  R. Motzer,et al.  Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. , 2007, The Lancet. Oncology.

[20]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[21]  A. Novick,et al.  Nephron sparing surgery for renal tumors: indications, techniques and outcomes. , 2001, The Journal of urology.

[22]  J. Patard,et al.  Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. , 2011, European urology.

[23]  P. Tamboli,et al.  Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. , 2011, European urology.

[24]  G. Striker.  Modification of diet in renal disease. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.